Nevertheless, in contrast to past findings, we found that the CYP1A2 AA, CA, and CA + AA genotypes were associated with an increased risk of prostate cancer (Table 4) and that the CYP1A2 CA + AA genotype (OR, 4.01; 95% CI, 1.60–10.05; P for interaction, 0.003) was higher than the CC genotype (OR, 2.65; 95% CI, 0.97–7.29) among individuals with high HAA intake, even though the CC genotype OR is not statistically significant, we still can find the trend (Table 5). The gene discussed is CYP1A2; the disease is prostate carcinoma.